I-κBα depletion by transglutaminase 2 and μ-calpain occurs in parallel with the ubiquitin-proteasome pathway

Biochemical and Biophysical Research Communications

Volumn 399, Issue 2, 2010, Pages 300-306

  Kim, Dae Seok ^a,b   Han, Byeong Gu ^a   Park, Kang Seo ^a   Il Lee, Byung ^a   Kim, Soo Youl ^a   Bae, Chang Dae ^b  

^a National Cancer Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Calpain; I B ; NF B; Proteasome; Transglutaminase 2

Indexed keywords

CALPAIN; I KAPPA B ALPHA; MICRO CALPAIN; POLYMER; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; UBIQUITIN; UNCLASSIFIED DRUG; CALPAIN 1; CALPEPTIN; CYSTAMINE; DIPEPTIDE; GUANINE NUCLEOTIDE BINDING PROTEIN; I KAPPA B; MU-CALPAIN; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PROTEASOME; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SMALL INTERFERING RNA;

ARTICLE; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LYSOSOME; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; DRUG ANTAGONISM; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

CALPAIN; CELL LINE, TUMOR; CYSTAMINE; DIPEPTIDES; GTP-BINDING PROTEINS; HUMANS; I-KAPPA B PROTEINS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, SMALL INTERFERING; TRANSGLUTAMINASES; UBIQUITIN;

EID: 77955841190     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.07.078     Document Type: Article

References (28)

1. Hacker H., Redecke V., Blagoev B., Kratchmarova I., Hsu L.C., Wang G.G., Kamps M.P., Raz E., Wagner H., Hacker G., Mann M., Karin M. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 2006, 439:204-207.
2. Palombella V.J., Rando O.J., Goldberg A.L., Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78:773-785.
3. Tergaonkar V., Bottero V., Ikawa M., Li Q., Verma I.M. IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy. Mol. Cell. Biol. 2003, 23:8070-8083.
4. Kim S.Y. Transglutaminase 2 in inflammation. Front. Biosci. 2006, 11:3026-3035.
5. Lee J., Kim Y.S., Choi D.H., Bang M.S., Han T.R., Joh T.H., Kim S.Y. Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J. Biol. Chem. 2004, 279:53725-53735.
6. Kim D.S., Park S.S., Nam B.H., Kim I.H., Kim S.Y. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res. 2006, 66:10936-10943.
7. Verma A., Mehta K. Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist. Updat. 2007, 10:144-151.
8. Ai L., Kim W.J., Demircan B., Dyer L.M., Bray K.J., Skehan R.R., Massoll N.A., Brown K.D. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis 2008, 29:510-518.
9. Park K.S., Kim D.S., Jeong K.C., Kim S.Y. Increase in transglutaminase 2 expression is associated with NF-kappaB activation in breast cancer tissues. Front. Biosci. 2009, 14:1945-1951.
10. Folk J.E., Chung S.I. Transglutaminases. Methods Enzymol. 1985, 113:358-375.
11. Park S.S., Kim J.M., Kim D.S., Kim I.H., Kim S.Y. Transglutaminase 2 mediates polymer formation of I-kappaBalpha through C-terminal glutamine cluster. J. Biol. Chem. 2006, 281:34965-34972.
12. Han J.A., Park S.C. Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line. J. Cancer Res. Clin. Oncol. 1999, 125:89-95.
13. Antonyak M.A., Miller A.M., Jansen J.M., Boehm J.E., Balkman C.E., Wakshlag J.J., Page R.L., Cerione R.A. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J. Biol. Chem. 2004, 279:41461-41467.
14. Mehta K., Fok J., Miller F.R., Koul D., Sahin A.A. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin. Cancer Res. 2004, 10:8068-8076.
15. Wilhelmus M.M., van Dam A.M., Drukarch B. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases. Eur. J. Pharmacol. 2008, 585:464-472.
16. Park S.S., Kim D.S., Park K.S., Song H.J., Kim S.Y. Proteomic analysis of high-molecular-weight protein polymers in a doxorubicin-resistant breast-cancer cell line. Proteomics Clin. Appl. 2007, 1:555-560.
17. Piacentini M., Amendola A., Ciccosanti F., Falasca L., Farrace M.G., Mastroberardino P.G., Nardacci R., Oliverio S., Piredda L., Rodolfo C., Autuori F. Type 2 transglutaminase and cell death. Prog. Exp. Tumor Res. 2005, 38:58-74.
18. Sorimachi H., Ishiura S., Suzuki K. Structure and physiological function of calpains. Biochem. J. 1997, 328(Pt. 3):721-732.
19. Suzuki K., Hata S., Kawabata Y., Sorimachi H. Structure, activation, and biology of calpain. Diabetes 2004, 53(Suppl. 1):S12-S18.
20. Thompson V.F., Saldana S., Cong J., Luedke D.M., Goll D.E. The calpain system in human placenta. Life Sci. 2002, 70:2493-2508.
21. Sato-Kusubata K., Yajima Y., Kawashima S. Persistent activation of Gsalpha through limited proteolysis by calpain. Biochem. J. 2000, 347(Pt. 3):733-740.
22. Kishimoto A., Kajikawa N., Shiota M., Nishizuka Y. Proteolytic activation of calcium-activated, phospholipid-dependent protein kinase by calcium-dependent neutral protease. J. Biol. Chem. 1983, 258:1156-1164.
23. Mendel D.B., Holbrook N.J., Bodwell J.E. Degradation without apparent change in size of molybdate-stabilized nonactivated glucocorticoid-receptor complexes in rat thymus cytosol. J. Biol. Chem. 1985, 260:8736-8740.
24. Perrin B.J., Amann K.J., Huttenlocher A. Proteolysis of cortactin by calpain regulates membrane protrusion during cell migration. Mol. Biol. Cell 2006, 17:239-250.
25. Baghdiguian S., Martin M., Richard I., Pons F., Astier C., Bourg N., Hay R.T., Chemaly R., Halaby G., Loiselet J., Anderson L.V., Lopez de Munain A., Fardeau M., Mangeat P., Beckmann J.S., Lefranc G. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Nat. Med. 1999, 5:503-511.
26. Han Y., Weinman S., Boldogh I., Walker R.K., Brasier A.R. Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappab activation. J. Biol. Chem. 1999, 274:787-794.
27. Miyamoto S., Seufzer B.J., Shumway S.D. Novel IkappaB alpha proteolytic pathway in WEHI231 immature B cells. Mol. Cell. Biol. 1998, 18:19-29.
28. Lee F.Y., Kim D.W., Karmin J.A., Hong D., Chang S.S., Fujisawa M., Takayanagi H., Bigliani L.U., Blaine T.A., Lee H.J. Mu-Calpain regulates receptor activator of NF-kappaB ligand (RANKL)-supported osteoclastogenesis via NF-kappaB activation in RAW 264.7 cells. J. Biol. Chem. 2005, 280:29929-29936.